Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning this approach. We performed a retrospective study involving 22 EBMT-affiliated cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tilmont, Rémi, Yakoub-Agha, Ibrahim, Eikema, Diderik-Jan, Zinger, Nienke, Haenel, Mathias, Schaap, Nicolaas, Arroyo, Concepcion Herrera, Schuermans, Christine, Besemer, Britta, Engelhardt, Monika, Kuball, Jürgen, Michieli, Mariagrazia, Schub, Natalie, Wilson, Keith M. O., Bourhis, Jean Henri, Mateos, Maria Victoria, Rabin, Neil, Jost, Edgar, Kröger, Nicolaus, Moraleda, José M, Za, Tommaso, Hayden, Patrick J., Beksac, Meral, Mclornan, Donal, Schönland, Stefan, Manier, Salomon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622318/
https://www.ncbi.nlm.nih.gov/pubmed/37543712
http://dx.doi.org/10.1038/s41409-023-02048-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622318/
https://www.ncbi.nlm.nih.gov/pubmed/37543712
http://dx.doi.org/10.1038/s41409-023-02048-7

Ejemplares similares